Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
70.54
USD
-0.92 (-1.29%)
Official Closing Price
Updated: 7:59 PM EDT, Apr 9, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
March 23, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administrat
March 18, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
March 15, 2021
From
GlobeNewswire News Releases
AavantiBio Bolsters Leadership Team with Appointment of Ty Howton as Chief Operating Officer and General Counsel
March 11, 2021
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel....
From
Business Wire News Releases
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investor Notice: Investigation over Potential Wrongdoing
March 08, 2021
San Diego, CA -- (SBWIRE) -- 03/08/2021 -- Certain directors of Sarepta Therapeutics, Inc are under investigation concerning potential breaches of fiduciary duties.
From
SBWire - Latest Press Releases
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
March 01, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
February 25, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics to Present at Upcoming Investor Conferences
February 24, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
February 22, 2021
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
February 04, 2021
Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
February 04, 2021
From
GlobeNewswire News Releases
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
February 01, 2021
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:...
From
PR Newswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 29, 2021
From
GlobeNewswire News Releases
NASDAQ:SRPT Shareholder Notice: Investigation over Potential Securities Laws Violations by Sarepta Therapeutics, Inc.
January 18, 2021
San Diego, CA -- (SBWIRE) -- 01/18/2021 -- Sarepta Therapeutics, Inc is under investigation over potential securities laws in connection with certain financial statements.
From
SBWire - Latest Press Releases
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
January 13, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
January 12, 2021
From
GlobeNewswire News Releases
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
January 12, 2021
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
From
Business Wire News Releases
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm
January 12, 2021
From
GlobeNewswire News Releases
SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Fir
January 09, 2021
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from...
From
PR Newswire
SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws
January 08, 2021
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. ("Sarepta" or the...
From
PR Newswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
January 08, 2021
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc.
From
Business Wire News Releases
SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. – SRPT
January 08, 2021
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from...
From
Business Wire News Releases
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 08, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
January 07, 2021
From
GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2020
From
GlobeNewswire News Releases
Sarepta Therapeutics Announces Executive Management Changes
December 14, 2020
From
GlobeNewswire News Releases
Should you invest in General Electric, Sarepta Therapeutics, Carnival Corp, Boeing, or Caterpillar?
December 07, 2020
InvestorsObserver issues critical PriceWatch Alerts for GE, SRPT, CCL, BA, and CAT.
From
PR Newswire
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
December 07, 2020
From
GlobeNewswire News Releases
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
December 04, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.